KD01
AXP000058.1 · Oncolytic virus
- Platform
- adenovirus
- Originator
- Tongji Hospital, Huazhong University of Science and Technology
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
Names
| Name | Type | Source |
|---|---|---|
| KD01 ambiguous | preferred name, code | curator, ctgov |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus (serotype not reported)
- Replication
- conditionally replicating
- Route
- intratumoral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07359235 | Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC) | Recruiting | Phase 1 | 2024-11-04 | 2028-12-31 | 29 | Bladder Cancer (BC) |
| NCT06552598 | The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies | Recruiting | Phase 1 | 2024-04-01 | 2028-04-01 | 97 | Cervical Cancer; Endometrial Cancer; Gynecologic Malignancies |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41761958 | Bevacizumab-Primed Vascular Normalization Enhances Intratumoral Delivery and Efficacy of the tBID-Armed Oncolytic Adenovirus KD01 in Glioma. | Frontiers in bioscience (Landmark edition) | 2026 | name in title: KD01 |
| PMID 42989365 | TBID-armed oncolytic adenovirus KD01 engages a CDCA8-associated mitotic vulnerability for anti-glioma therapy. | Virology journal | 2026 | name in title: KD01 |
| PMID 40033102 | Ferroptosis enhances the therapeutic potential of oncolytic adenoviruses KD01 against cancer. | Cancer gene therapy | 2025 | name in title: KD01 |
| PMID 40283946 | Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer. | Pharmaceuticals (Basel, Switzerland) | 2025 | name in title: KD01 |
| PMID 38734262 | Degradation of organic mercury in high salt environments by a marine aerobic bacterium Alteromonas macleodii KD01. | Bioresource technology | 2024 | name in title: KD01 |
| PMID 38007712 | Superoxide-Mediated Extracellular Mercury Reduction by Aerobic Marine Bacterium Alteromonas sp. KD01. | Environmental science & technology | 2023 | name in title: KD01 |
Unconfirmed matches (2)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40057574 | Chimeric Ad5/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency. | Cancer gene therapy | 2025 | name in abstract: KD01 |
| PMID 40813343 | Discovery of asymmetric pyridinium-based fluorescent probes with large Stokes shifts for live neural stem/progenitor cells. | Journal of materials chemistry. B | 2025 | name in abstract: KD01 |
Notes
Recombinant oncolytic adenovirus in phase I trials in gynaecological malignancies (NCT06552598) and a second Tongji trial (NCT07359235); preclinical work also in bladder cancer. Construct not described in sources consulted.
How to cite
KD01 (AXP000058.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000058.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.